Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence.
Igarashi, Ataru; Kaur, Harneet; Choubey, Abhay; Popli, Akshay; Muthukumar, Madhusubramanian; Yoshisue, Hajime; Funakubo, Minako; Ohta, Ken.
Afiliación
  • Igarashi A; Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. Electronic address: atarui1@mac.com.
  • Kaur H; Value & Access, CONEXTS, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
  • Choubey A; Value & Access, CONEXTS, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
  • Popli A; Value & Access, CONEXTS, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
  • Muthukumar M; Value & Access, CONEXTS, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
  • Yoshisue H; Medical Division, Novartis Pharma KK, Tokyo, Japan.
  • Funakubo M; Health Economic & Outcomes Research, Novartis Pharma KK, Tokyo, Japan.
  • Ohta K; Department of Respiratory Medicine and Allergology, Japan Anti-Tuberculosis Association (JATA), Fukujuji Hospital, Tokyo, Japan.
Value Health Reg Issues ; 27: 41-48, 2022.
Article en En | MEDLINE | ID: mdl-34784547
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Asma / Antiasmáticos Tipo de estudio: Clinical_trials / Health_economic_evaluation Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Value Health Reg Issues Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Asma / Antiasmáticos Tipo de estudio: Clinical_trials / Health_economic_evaluation Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Value Health Reg Issues Año: 2022 Tipo del documento: Article